Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Table 1.

Therapy grouping method for primary and secondary analyses.

More »

Table 1 Expand

Fig 1.

PRISMA flow chart.

More »

Fig 1 Expand

Fig 2.

Network geometry.

Note: BP = blood product; BPcombo = blood product combination therapy; Botox = botulinum toxin; CS = corticosteroid; CScombo = corticosteroid combination therapy; HA = hyaluronic acid; Noninj = non-injections; Pcb = placebo; Prolo = prolotherapy; Prolocombo = prolotherapy combination therapy. The size of the node corresponds to the number of participants assigned to the intervention while thickness of the connecting line corresponds to the number of the studies included.

More »

Fig 2 Expand

Fig 3.

Interval plot of treatment efficacy relative to placebo.

Note: BP = blood product; BPcombo = blood product combination therapy; Botox = botulinum toxin; CS = corticosteroid; CScombo = corticosteroid combination therapy; HA = hyaluronic acid; Noninj = non-injections; Pcb = placebo; Prolo = prolotherapy.

More »

Fig 3 Expand

Fig 4.

Risk of bias of individual study.

More »

Fig 4 Expand

Fig 5.

Functional outcome.

Note: BP = blood product; BPcombo = blood product combination therapy; Botox = botulinum toxin; CS = corticosteroid; CScombo = corticosteroid combination therapy; HA = hyaluronic acid; Noninj = non-injections; Pcb = placebo; Prolo = prolotherapy.

More »

Fig 5 Expand